Ready to order?
Register / LoginBPC-157 and TB-500 are two of the most frequently examined synthetic peptides in laboratory research, and they are often studied side by side. Investigators working on cellular signalling, cytoskeletal dynamics and tissue biology have looked at BPC157 TB500 together because the two molecules appear to act through separate and potentially complementary mechanisms.
This article is a research overview of BPC157 TB500 as a combined subject of study. It covers the properties of each peptide, why they are examined together, how the pre-mixed blend format is used, and what to verify when sourcing either compound. It does not describe quantities, preparation or experimental design — those are determined by the receiving laboratory.
Overview: BPC-157 and TB-500 as Research Subjects
BPC-157 (Body Protection Compound 157) and TB-500 are two distinct synthetic peptides, each with a substantial body of laboratory literature behind it. They are different molecules acting through different mechanisms, but researchers have identified areas of biological overlap that make examining them in combination a logical extension of work on each individually.
The BPC 157 TB500 combination is most often examined in blend form, where investigators look at how the simultaneous presence of both peptides affects observed outcomes compared with either peptide alone.
What Is BPC-157?
BPC-157 is a pentadecapeptide — a chain of fifteen amino acids — whose sequence corresponds to a fragment of a protective protein identified in gastric juice. It does not occur in this isolated synthetic form in nature. Published work has examined it in relation to angiogenesis, nitric oxide signalling, growth factor interactions and gastrointestinal biology, predominantly in animal and in vitro models.
Characteristics noted in the research literature:
- Fifteen amino acid sequence (pentadecapeptide)
- Reported stability in biological fluids
- Examined in relation to VEGF and angiogenic pathways
- Studied alongside nitric oxide (NO) signalling systems
- Supplied as lyophilised powder in vial and blend formats
For a fuller treatment of BPC-157 on its own, see our article: What Is BPC-157? Complete Research Overview.
What Is TB-500?
TB-500 is a synthetic peptide corresponding to a short active region of thymosin beta-4, a protein present in most mammalian cells. More precisely, TB-500 is the acetylated seven-residue fragment Ac-LKKTETQ, corresponding to positions 17 to 23 of the parent protein.
That distinction matters when reading the literature. Listings across the sector often treat “TB-500” and “thymosin beta-4” as interchangeable terms, but research conducted on the full 43-residue protein does not automatically characterise the shorter synthetic fragment.
Characteristics noted in the research literature:
- Corresponds to a defined fragment of the thymosin beta-4 sequence
- Associated with actin binding and cytoskeletal regulation
- Examined in models of angiogenesis and cell migration
- Referenced in work on inflammatory signalling pathways
- Supplied as lyophilised powder in vial format
For a fuller treatment of TB-500 on its own, see our article: TB-500 Peptide: Biological Properties and Research Applications.
Why Researchers Examine BPC-157 and TB-500 Together
The rationale for examining BPC 157 and TB500 together comes from their distinct but potentially complementary mechanisms. Several reasons appear consistently in the literature.
Overlapping areas of biological interest
Both compounds have been examined in relation to angiogenesis, the formation of new blood vessels. They appear to influence that process through different molecular routes, which raises the question of whether their combined presence affects angiogenic signalling differently from either compound alone.
Different molecular targets
BPC-157 has been studied largely in relation to growth factor receptors and nitric oxide pathways. TB-500 is associated with actin regulatory proteins and cellular migration. Because the two engage different systems, examining them together allows investigators to observe several pathways within a single model.
The evidence base is thinner than the interest
It is worth being direct about this: the pairing is discussed considerably more often than it has been tested. Controlled research on the two compounds studied together is limited, and much of the interest in the combination is extrapolated from separate bodies of work on each peptide. Researchers designing work in this area should treat the combination as an open question rather than a settled one.
The BPC-157 TB-500 Blend as a Research Format
The BPC 157 TB 500 blend is a recognised research format supplied as a single pre-mixed lyophilised preparation containing both compounds at a fixed ratio. For laboratories examining both peptides, the blend removes a preparation step and holds the compound ratio consistent across a batch.
Meta Molecule supplies the BPC157 TB500 blend as a 5mg / 5mg preparation. Compound ratio, batch identity and purity are recorded on the certificate of analysis that accompanies each batch.
Comparing the Two Compounds
|
Attribute |
BPC-157 |
TB-500 |
| Class | Synthetic pentadecapeptide | Synthetic peptide fragment |
| Sequence origin | Fragment of a gastric protein sequence | Residues 17–23 of thymosin beta-4 |
| Length | 15 amino acids | 7 amino acids (acetylated) |
| Mechanisms described | Growth factor receptors, nitric oxide signalling, angiogenesis | Actin binding, cytoskeletal regulation, cell migration |
| Predominant models | Animal and in vitro | In vitro and animal |
| Regulatory status | Not approved for any clinical indication | Not approved for any clinical indication |
| Supplied form | Lyophilised powder | Lyophilised powder |
Sourcing BPC-157 and TB-500 for Laboratory Research
Researchers looking to work with BPC157 and TB500 have two sourcing routes.
Individual compounds
BPC-157 and TB-500 can each be sourced separately as lyophilised vials. This route lets a laboratory set the ratio of the two compounds independently according to its own study design.
Pre-mixed blend
The BPC-157 TB-500 blend arrives as a single vial containing both peptides at a fixed ratio, which suits work that calls for a consistent preparation across a batch without a separate mixing step.
Meta Molecule carries both individual compounds and the BPC 157 TB 500 blend in the research catalogue. Every product ships with a full certificate of analysis confirming purity and batch testing. Registration is required to access the shop.
Quality Standards for Research Peptides
When sourcing any research peptide, including BPC-157 and TB-500, verification matters more than price. Confirm the following before material enters a workflow:
- Third-party testing with an available certificate of analysis for every batch
- Purity of 98% or higher (Meta Molecule maintains 99%)
- Proper lyophilisation supporting peptide stability
- Accurate labelling of peptide content per vial
- Secure, tamper-evident packaging appropriate for laboratory handling
Match the batch identifier printed on the vial against the corresponding certificate of analysis before use. Sealed vials should be held in cold storage, protected from light and moisture, and allowed to reach ambient temperature before the seal is broken. Handling and disposal remain the responsibility of the receiving laboratory under its own established procedures.
Frequently Asked Questions: BPC-157 and TB-500
Q: What is the difference between BPC-157 and TB-500?
A: BPC-157 is a fifteen amino acid peptide based on a gastric protein sequence, examined largely in relation to growth factor receptors and nitric oxide pathways. TB-500 is a seven-residue fragment corresponding to a region of thymosin beta-4, examined in relation to actin regulation and cell migration. They are unrelated in sequence and are described through different mechanisms.
Q: Why do researchers examine BPC-157 and TB-500 together?
A: Because the two engage different biological systems — BPC157 primarily growth factor and nitric oxide pathways, TB500 actin and cellular migration — examining them together allows several pathways to be observed within one model. Direct controlled research on the combination remains limited.
Q: What is the BPC-157 TB-500 blend?
A: The BPC 157 TB 500 blend is a pre-mixed lyophilised research preparation containing both peptides at a fixed ratio in a single vial, removing the need to prepare two separate solutions.
Q: Are BPC-157 or TB-500 approved for clinical use?
A: No. Neither compound is approved by the FDA or any comparable regulator for any clinical indication, and neither is available as a prescription medicine. Both are supplied strictly as laboratory research materials and are not for human or veterinary use.
Q: What purity should BPC-157 and TB-500 have for research use?
A: For reliable laboratory work, peptides should test at 98% purity or higher. Meta Molecule supplies BPC-157 and TB-500 at 99% purity, verified through third-party batch testing with publicly available certificates of analysis.
DISCLAIMER: This article is intended for educational and informational purposes relating to biochemical and laboratory research. It does not constitute medical advice and is not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA. Research peptides are supplied solely for laboratory study by qualified professional researchers and are not intended for human or veterinary consumption.
